Hyperfine (NASDAQ:HYPR) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Hyperfine (NASDAQ:HYPR) from a hold rating to a sell rating in a report issued on Sunday morning,Wall Street Zen reports.

Several other analysts have also issued reports on HYPR. Lucid Cap Mkts assumed coverage on shares of Hyperfine in a research report on Tuesday, October 27th. They issued a “strong-buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperfine in a research report on Thursday, October 15th. B. Riley Financial reaffirmed a “buy” rating and set a $1.60 price objective (down from $2.00) on shares of Hyperfine in a research report on Monday, August 10th. BTIG Research reiterated a “buy” rating and issued a $2.00 target price on shares of Hyperfine in a research note on Tuesday, September 22nd. Finally, Loop Capital set a $2.00 target price on Hyperfine in a research report on Tuesday, October 27th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Hyperfine presently has a consensus rating of “Moderate Buy” and a consensus target price of $2.02.

Hyperfine Stock Down 3.6%

HYPR opened at $0.68 on Friday. Hyperfine has a 1-year low of $0.67 and a 1-year high of $1.94. The company has a current ratio of 6.15, a quick ratio of 5.45 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $72.24 million, a price-to-earnings ratio of -2.27 and a beta of 1.49. The business has a 50 day moving average of $0.79 and a 200-day moving average of $1.11.

Hyperfine (NASDAQ:HYPR) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. Hyperfine had a negative net margin of 156.42% and a negative return on equity of 87.74%. The business had revenue of $5.96 million for the quarter, compared to the consensus estimate of $5.84 million. As a group, sell-side analysts anticipate that Hyperfine will post -0.34 earnings per share for the current year.

Institutional Investors Weigh In On Hyperfine

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in shares of Hyperfine by 100.2% in the 1st quarter. Renaissance Technologies LLC now owns 730,233 shares of the company’s stock worth $789,000 after buying an additional 365,490 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Hyperfine by 7,695.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 487,994 shares of the company’s stock valued at $394,000 after buying an additional 481,734 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Hyperfine in the second quarter valued at $419,000. Walleye Capital LLC grew its position in Hyperfine by 3.4% in the first quarter. Walleye Capital LLC now owns 223,988 shares of the company’s stock valued at $242,000 after acquiring an additional 7,330 shares during the period. Finally, PFS Partners LLC grew its position in Hyperfine by 150.0% in the third quarter. PFS Partners LLC now owns 50,000 shares of the company’s stock valued at $40,000 after acquiring an additional 30,000 shares during the period. 15.03% of the stock is currently owned by institutional investors.

Hyperfine Company Profile

Hyperfine, Inc. (NASDAQ: HYPR) is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings. Hyperfine’s primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient’s bedside. The system is designed to produce brain images without requiring patients to be transported to a traditional radiology department.